Klinisk Biokemi i Norden · 4 2015
| 25
and molecular bases of inherited disease. 8th
Ed. New York: McGraw-Hill 2001:2835-62.
14. Havel RJ, Kane JP. Introduction: structure
and metabolism of plasma lipoproteins. In:
Scriver CR, Beaudet AL, Sly WS, Valle D, eds.
The metabolic and molecular bases of inheri-
ted disease. 8th Ed. New York: McGraw-Hill
2001:2705-16.
15. Rasmussen KL, Tybjaerg-Hansen A, Nordest-
gaard BG, Frikke-Schmidt R. Plasma levels of
apolipoprotein E and risk of dementia in the
general population. Ann Neurol 2015;77:301-
311.
16. Frikke-Schmidt R, Nordestgaard BG, Ager-
holm-Larsen B, Schnohr P, Tybjaerg-Hansen
A. Context-dependent and invariant associa-
tions between lipids, lipoproteins, and apoli-
poproteins and apolipoprotein E genotype. J
Lipid Res 2000;41:1812-22.
17. Siest G, Bertrand P, Qin B, Herbeth B,
Serot JM, Masana L, et al. Apolipoprotein E
polymorphism and serum concentration in
Alzheimer’s disease in nine European centres:
the ApoEurope study. ApoEurope group. Clin
Chem Lab Med 2000;38:721-30.
18. Jack CR, Jr., Knopman DS, Jagust WJ,
Petersen RC, Weiner MW, Aisen PS, et al.
Tracking pathophysiological processes in
Alzheimer’s disease: an updated hypothetical
model of dynamic biomarkers. Lancet Neurol
2013;12:207-16.
19. Cruchaga C, Kauwe JS, Nowotny P, Bales K,
Pickering EH, Mayo K, et al. Cerebrospinal
fluid APOE levels: an endophenotype for
genetic studies for Alzheimer’s disease. Hum
Mol Genet 2012;21:4558-71.
20. Frikke-Schmidt R, Nordestgaard BG, Stene
MC, Sethi AA, Remaley AT, Schnohr P, et al.
Association of loss-of-function mutations in
the ABCA1 gene with high-density lipopro-
tein cholesterol levels and risk of ischemic
heart disease. JAMA 2008;299:2524-32.
21. Zacho J, Tybjaerg-Hansen A, Jensen JS,
Grande P, Sillesen H, Nordestgaard BG.
Genetically elevated C-reactive protein and
ischemic vascular disease. N Engl J Med
2008;359:1897-908.
22. Kamstrup PR, Tybjaerg-Hansen A, Steffensen
R, Nordestgaard BG. Genetically elevated
lipoprotein(a) and increased risk of myocar-
dial infarction. JAMA 2009;301:2331-9.
23. Friedewald WT, Levy RI, Fredrickson DS.
Estimation of the concentration of low-den-
sity lipoprotein cholesterol in plasma, without
use of the preparative ultracentrifuge. Clin
Chem 1972;18:499-502.
24. Clarke R, Shipley M, Lewington S, Youngman
L, Collins R, Marmot M, et al. Underestima-
tion of risk associations due to regression
dilution in long-term follow-up of prospective
studies. Am J Epidemiol 1999;150:341-53.
25. Vijayaraghavan S, Maetzler W, Reimold M,
Lithner CU, Liepelt-Scarfone I, Berg D, et al.
High apolipoprotein E in cerebrospinal fluid
of patients with Lewy body disorders is asso-
ciated with dementia. Alzheimers Dement
2014;10:530-40.
26. Liu M, Kuhel DG, Shen L, Hui DY, Woods SC.
Apolipoprotein E does not cross the blood-
cerebrospinal fluid barrier, as revealed by an
improved technique for sampling CSF from
mice. Am J Physiol Regul Integr Comp Phy-
siol 2012;303:R903-R908.
27. Linton MF, Gish R, Hubl ST, Butler E, Esqui-
vel C, Bry WI, et al. Phenotypes of apolipo-
protein B and apolipoprotein E after liver
transplantation. J Clin Invest 1991;88:270-81.
28. Hyman BT, Holtzman DM. Apolipoprotein
E levels and Alzheimer risk. Ann Neurol
2015;77:204-5.
29. Catapano AL, Reiner Z, De BG, Graham I,
Taskinen MR, Wiklund O, et al. ESC/EAS
Guidelines for the management of dyslipi-
daemias The Task Force for the management
of dyslipidaemias of the European Society of
Cardiology (ESC) and the European Athe-
rosclerosis Society (EAS). Atherosclerosis
2011;217:3-46.
